Psychedelic Medicine Pioneer Leaves Lykos Therapeutics Following FDA Regulatory Challenges
Thursday, 15 August 2024, 17:59
Psychedelic Medicine Pioneer Resigns
The recent exit of Doblin from the board of Lykos Therapeutics highlights the challenges facing the psychedelic medicine sector. Following an unfavorable ruling from the FDA, the development of MDMA-based treatments for PTSD has encountered significant obstacles.
Impact of FDA Decision
- The FDA ruling has raised concerns about the viability of MDMA therapy for patients with PTSD.
- This setback has repercussions for both research timelines and funding opportunities in the psychedelic space.
Future Considerations
With Doblin's departure, the trajectory of Lykos Therapeutics remains uncertain as they navigate these challenging waters.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.